204 related articles for article (PubMed ID: 35929461)
1. Characterization of Polyvascular Disease in Heterozygous Familial Hypercholesterolemia: Its Association With Circulating Lipoprotein(a) Levels.
Funabashi S; Kataoka Y; Hori M; Ogura M; Doi T; Noguchi T; Harada-Shiba M
J Am Heart Assoc; 2022 Aug; 11(16):e025232. PubMed ID: 35929461
[TBL] [Abstract][Full Text] [Related]
2. Polyvascular subclinical atherosclerosis in familial hypercholesterolemia: The role of cholesterol burden and gender.
Mattina A; Giammanco A; Giral P; Rosenbaum D; Carrié A; Cluzel P; Redheuil A; Bittar R; Béliard S; Noto D; Quartarone A; Averna M; Bruckert É; Gallo A
Nutr Metab Cardiovasc Dis; 2019 Oct; 29(10):1068-1076. PubMed ID: 31378630
[TBL] [Abstract][Full Text] [Related]
3. The different relations of PCSK9 and Lp(a) to the presence and severity of atherosclerotic lesions in patients with familial hypercholesterolemia.
Cao YX; Liu HH; Sun D; Jin JL; Xu RX; Guo YL; Wu NQ; Zhu CG; Li S; Zhang Y; Sun J; Li JJ
Atherosclerosis; 2018 Oct; 277():7-14. PubMed ID: 30170223
[TBL] [Abstract][Full Text] [Related]
4. Lipoprotein(a) level associates with coronary artery disease rather than carotid lesions in patients with familial hypercholesterolemia.
Sun D; Zhou BY; Zhao X; Li S; Zhu CG; Guo YL; Gao Y; Wu NQ; Liu G; Dong Q; Li JJ
J Clin Lab Anal; 2018 Sep; 32(7):e22442. PubMed ID: 29603377
[TBL] [Abstract][Full Text] [Related]
5. Association between lipoprotein (a) and proprotein convertase substilisin/kexin type 9 in patients with heterozygous familial hypercholesterolemia: A case-control study.
Sun D; Li S; Zhao X; Wu NQ; Zhu CG; Guo YL; Gao Y; Qing P; Cui CJ; Liu G; Sun J; Dong Q; Li JJ
Metabolism; 2018 Feb; 79():33-41. PubMed ID: 29129821
[TBL] [Abstract][Full Text] [Related]
6. Physical signs and atherosclerotic cardiovascular disease in familial hypercholesterolemia: the HELLAS-FH Registry.
Rallidis LS; Rizos CV; Papathanasiou KA; Liamis G; Skoumas I; Garoufi A; Kolovou G; Tziomalos K; Skalidis E; Kotsis V; Sfikas G; Doumas M; Anagnostis P; Lambadiari V; Giannakopoulou V; Kiouri E; Anastasiou G; Petkou E; Koutagiar I; Attilakos A; Kolovou V; Zacharis E; Antza C; Koumaras C; Boutari C; Liberopoulos E
J Cardiovasc Med (Hagerstown); 2024 May; 25(5):370-378. PubMed ID: 38526957
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of heterozygous familial hypercholesterolemia and combined hyperlipidemia phenotype in very young survivors of myocardial infarction and their association with the severity of atheromatous burden.
Rallidis LS; Kosmas N; Tsirebolos G; Rallidi M; Kiouri E; Kalpakos D
J Clin Lipidol; 2019; 13(3):502-508. PubMed ID: 30956097
[TBL] [Abstract][Full Text] [Related]
8. Familial hypercholesterolemia and elevated lipoprotein(a): double heritable risk and new therapeutic opportunities.
Vuorio A; Watts GF; Schneider WJ; Tsimikas S; Kovanen PT
J Intern Med; 2020 Jan; 287(1):2-18. PubMed ID: 31858669
[TBL] [Abstract][Full Text] [Related]
9. Association between lipoprotein(a) concentrations and atherosclerotic cardiovascular disease risk in patients with familial hypercholesterolemia: an analysis from the HELLAS-FH.
Anagnostis P; Rizos CV; Skoumas I; Rallidis L; Tziomalos K; Skalidis E; Kotsis V; Doumas M; Kolovou G; Sfikas G; Garoufi A; Lambadiari V; Dima I; Kiouri E; Agapakis D; Zacharis E; Antza C; Kolovou V; Koumaras C; Bantouvakis G; Liamis G; Liberopoulos EN
Endocrine; 2022 May; 76(2):324-330. PubMed ID: 35262845
[TBL] [Abstract][Full Text] [Related]
10. Lipoprotein(a) is associated with DNA damage in patients with heterozygous familial hypercholesterolemia.
Woźniak E; Broncel M; Woźniak A; Satała J; Pawlos A; Bukowska B; Gorzelak-Pabiś P
Sci Rep; 2024 Jan; 14(1):2564. PubMed ID: 38297066
[TBL] [Abstract][Full Text] [Related]
11. Lipoprotein(a) in hereditary hypercholesterolemia: Influence of the genetic cause, defective gene and type of mutation.
Marco-Benedí V; Cenarro A; Laclaustra M; Larrea-Sebal A; Jarauta E; Lamiquiz-Moneo I; Calmarza P; Bea AM; Plana N; Pintó X; Martín C; Civeira F
Atherosclerosis; 2022 May; 349():211-218. PubMed ID: 34456049
[TBL] [Abstract][Full Text] [Related]
12. Lipoprotein(a) levels in children with homozygous familial hypercholesterolaemia: A cross-sectional study.
de Boer LM; Reijman MD; Hutten BA; Wiegman A
J Clin Lipidol; 2023; 17(3):415-419. PubMed ID: 37087364
[TBL] [Abstract][Full Text] [Related]
13. Oxidative stress-responsive apoptosis-inducing protein in patients with heterozygous familial hypercholesterolemia.
Sato K; Yao T; Fujimura T; Murayama K; Okumura K; Hagiwara N; Seko Y
Heart Vessels; 2021 Dec; 36(12):1923-1932. PubMed ID: 34308503
[TBL] [Abstract][Full Text] [Related]
14. How Can We Identify Very High-Risk Heterozygous Familial Hypercholesterolemia?
Kataoka Y; Funabashi S; Doi T; Harada-Shiba M
J Atheroscler Thromb; 2022 Jun; 29(6):795-807. PubMed ID: 35022364
[TBL] [Abstract][Full Text] [Related]
15. Mature proprotein convertase subtilisin/kexin type 9, coronary atheroma burden, and vessel remodeling in heterozygous familial hypercholesterolemia.
Kataoka Y; Harada-Shiba M; Nakao K; Nakashima T; Kawakami S; Fujino M; Kanaya T; Nagai T; Tahara Y; Asaumi Y; Hori M; Ogura M; Goto Y; Noguchi T; Yasuda S
J Clin Lipidol; 2017; 11(2):413-421.e3. PubMed ID: 28502498
[TBL] [Abstract][Full Text] [Related]
16. Maternally inherited hypercholesterolemia does not modify the cardiovascular phenotype in familial hypercholesterolemia.
Marco-Benedí V; Laclaustra M; Bea AM; Suarez-Tembra M; Plana N; Pinto X; Brea A; Sanchez-Hernandez RM; Civeira F
Atherosclerosis; 2021 Mar; 320():47-52. PubMed ID: 33529866
[TBL] [Abstract][Full Text] [Related]
17. Metabolic systems approaches update molecular insights of clinical phenotypes and cardiovascular risk in patients with homozygous familial hypercholesterolemia.
Du Z; Li F; Jiang L; Li L; Du Y; Yu H; Luo Y; Wang Y; Sun H; Hu C; Li J; Yang Y; Jiao X; Wang L; Qin Y
BMC Med; 2023 Jul; 21(1):275. PubMed ID: 37501168
[TBL] [Abstract][Full Text] [Related]
18. Resilient Older Subjects with Heterozygous Familial Hypercholesterolemia, Baseline Differences and Associated Factors.
Climent E; González-Guerrero A; Marco-Benedí V; García-Andreu MD; Mediavilla-García JD; Suárez-Tembra M; Benaiges D; Pintó X; Pedro-Botet J
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732050
[TBL] [Abstract][Full Text] [Related]
19. Relation of Serum Lipoprotein(a) Levels to Lipoprotein and Apolipoprotein Profiles and Atherosclerotic Diseases in Japanese Patients with Heterozygous Familial Hypercholesterolemia: Familial Hypercholesterolemia Expert Forum (FAME) Study.
Naito R; Daida H; Masuda D; Harada-Shiba M; Arai H; Bujo H; Ishibashi S; Koga N; Oikawa S; Yamashita S
J Atheroscler Thromb; 2022 Aug; 29(8):1188-1200. PubMed ID: 34456199
[TBL] [Abstract][Full Text] [Related]
20. Value of the Definition of Severe Familial Hypercholesterolemia for Stratification of Heterozygous Patients.
Pérez-Calahorra S; Sánchez-Hernández RM; Plana N; Marco-Benedi V; Pedro-Botet J; Almagro F; Brea A; Ascaso JF; Lahoz C; Civeira F;
Am J Cardiol; 2017 Mar; 119(5):742-748. PubMed ID: 28081939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
